ALKBH5 and neoplasm: Collectively, the in vivo studies showed that ALKBH5 promotes cancer progression by facilitating tumor growth and maintaining an immunosuppressive microenvironment, whereas anti-PD-L1 therapy is more effective in tumors with high ALKBH5 expression.